Terms: = Lymphoma AND ROS1, ROS, 6098, ENSG00000047936, P08922, MCF3, RP1-179P9_1 AND Treatment
27614 results:
1. Regulation of Mertk Surface Expression via ADAM17 and γ-Secretase Proteolytic Processing.
Lahey KC; Varsanyi C; Wang Z; Aquib A; Gadiyar V; Rodrigues AA; Pulica R; Desind S; Davra V; Calianese DC; Liu D; Cho JH; Kotenko SV; De Lorenzo MS; Birge RB
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673989
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France.
Alcazer V; Le Meur G; Roccon M; Barriere S; Le Calvez B; Badaoui B; Spaeth A; Kosmider O; Freynet N; Eveillard M; Croizier C; Chevalier S; Sujobert P
Lancet Digit Health; 2024 May; 6(5):e323-e333. PubMed ID: 38670741
[TBL] [Abstract] [Full Text] [Related]
3. Experience of multi-disciplinary treatment of multiple cerebellar diffuse large B-cell lymphoma: A case report.
Guo Y; Li J; Li M; Li Z; Cui Y; Li Y; Zhao R; Han Q; Yang H; Ma C
Medicine (Baltimore); 2024 Apr; 103(17):e37923. PubMed ID: 38669361
[TBL] [Abstract] [Full Text] [Related]
4. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
5. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
6. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
7. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell lymphoma Cells].
Zhang YL; Chen YH; Zheng RJ; Zheng KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
[TBL] [Abstract] [Full Text] [Related]
8. [Effect of L-Type Amino Acid Transporter 1 Expression on Clinicopathological Features and Prognosis of Non-Hodgkin's lymphoma].
Zhao ZF; Hao XJ; Yang YM; Xu WG; Zhang YX; Yuan XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):434-438. PubMed ID: 38660848
[TBL] [Abstract] [Full Text] [Related]
9. [A Real-World Single-Center Study of Adult Hodgkin's lymphoma].
Wang LL; Tian L; Dong F; Yang P; Wan W; Li QH; Ma L; Gao JJ; Wang JJ; Zhao W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):428-433. PubMed ID: 38660847
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line
Valizadeh Toosi SM; Feyzi S; Kazemi A
Korean J Gastroenterol; 2024 Apr; 83(4):150-156. PubMed ID: 38659251
[TBL] [Abstract] [Full Text] [Related]
11. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
12. Case report: EBV-related eye orbits and sinuses lymphohistiocytic infiltration responsive to rituximab in a patient with X lymphoproliferative syndrome type 1.
Giardino G; Lanni V; Mascolo M; Russo D; Cirillo E; Romano R; Cillo F; Grilli L; Prencipe MR; Iuliano A; Uccello G; De Fusco C; Menna G; Scalia G; Portella G; Pignata C
Front Immunol; 2024; 15():1370991. PubMed ID: 38633254
[TBL] [Abstract] [Full Text] [Related]
13. Current treatment and novel insights regarding ros1-targeted therapy in malignant tumors.
Li S; Zhang H; Chen T; Zhang X; Shang G
Cancer Med; 2024 Apr; 13(8):e7201. PubMed ID: 38629293
[TBL] [Abstract] [Full Text] [Related]
14. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H; Feng J; Liu Y; Qian Z; Gao D; Ran X; Zhou H; Liu L; Wang B; Fang M; Zhou H; Huang Z; Tao S; Chen Z; Su L; Su H; Yang Y; Xie X; Wu H; Sun P; Hu G; Liang A; Li Z
Signal Transduct Target Ther; 2024 Apr; 9(1):99. PubMed ID: 38627366
[TBL] [Abstract] [Full Text] [Related]
15. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract] [Full Text] [Related]
16. Reclassification of a spindle cell sarcoma after identification of a TFG-ros1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract] [Full Text] [Related]
17. A Rare Case of Methemoglobinemia after Ifosfamide Infusion in a 3-Year-Old Patient Treated for T-ALL.
Suprunowicz M; Marcinkiewicz K; Leszczyńska E; Krętowska-Grunwald A; Płonowski M; Tałałaj M; Dakowicz Ł; Krawczuk-Rybak M; Sawicka-Żukowska M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612599
[TBL] [Abstract] [Full Text] [Related]
18. Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities.
Kulczycka M; Derlatka K; Tasior J; Sygacz M; Lejman M; Zawitkowska J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612531
[TBL] [Abstract] [Full Text] [Related]
19. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
20. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
[Next]